Go Pro

Clearmind Medicine (CMND) 10K Form and Latest SEC Filings 2026

Clearmind Medicine logo
$1.70 -0.15 (-8.11%)
Closing price 09/3/2026 04:00 PM Eastern
Extended Trading
$1.70 0.00 (0.00%)
As of 04:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Clearmind Medicine SEC Filings & Recent Activity

Clearmind Medicine (NASDAQ:CMND) has submitted 216+ documents to the U.S. Securities and Exchange Commission (SEC) since 2022. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 6-K submitted on September 2, 2026.

Form 4
Clearmind Medicine Inc. Reports Ownership Change on Jun. 18, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

Clearmind Medicine SEC Filing History

Browse Clearmind Medicine's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
09/02/2026 3:01 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/01/2026 7:01 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/24/2026 3:00 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/12/2026 9:46 AM
Clearmind Medicine (1892500) Subject
Iroquois Capital Management, LLC (1481867) Filed by
Form SCHEDULE 13G/A
08/11/2026 3:01 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/03/2026 7:12 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/30/2026 3:01 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/20/2026 3:00 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/17/2026 3:01 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/16/2026 12:39 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/13/2026 3:01 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/10/2026 3:00 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/07/2026 3:01 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/29/2026 7:11 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/22/2026 7:08 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/21/2026 11:15 PM
Clearmind Medicine (1892500) Filer
Form EFFECT
06/18/2026 4:05 PM
Clearmind Medicine (1892500) Issuer
HRT FINANCIAL LP (1475597) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2026 7:11 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/17/2026 3:42 PM
Clearmind Medicine (1892500) Issuer
HRT FINANCIAL LP (1475597) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2026 8:19 AM
Clearmind Medicine (1892500) Issuer
HRT FINANCIAL LP (1475597) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2026 6:35 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/15/2026 4:09 PM
Clearmind Medicine (1892500) Filer
Form POS AM
06/15/2026 3:01 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/12/2026 3:19 PM
Clearmind Medicine (1892500) Issuer
HRT FINANCIAL LP (1475597) Reporting
Form 3
Initial statement of beneficial ownership of securities  
05/29/2026 7:35 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/26/2026 7:30 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/19/2026 5:51 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/19/2026 5:21 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/18/2026 3:05 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/15/2026 3:15 PM
Capitalink Ltd. (2036836) Filed by
Clearmind Medicine (1892500) Subject
Form SCHEDULE 13G/A
05/15/2026 3:15 PM
Clearmind Medicine (1892500) Subject
L.I.A. Pure Capital Ltd (1749628) Filed by
Form SCHEDULE 13G/A
05/12/2026 8:27 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/07/2026 11:15 PM
Clearmind Medicine (1892500) Filer
Form EFFECT
05/05/2026 7:53 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/30/2026 3:21 PM
Clearmind Medicine (1892500) Filer
Form F-3
Registration statement for securities of certain foreign private issuers  
04/27/2026 6:45 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/21/2026 5:57 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/20/2026 4:18 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/20/2026 3:05 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/15/2026 8:15 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/15/2026 6:00 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
Bezos… DOOMED (Ad)

A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25.tc pixel

Watch James Altucher's free video breakdown before the September 25 deadline.
04/14/2026 3:01 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/14/2026 7:23 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/30/2026 11:15 PM
Clearmind Medicine (1892500) Filer
Form EFFECT
03/30/2026 11:15 PM
Clearmind Medicine (1892500) Filer
Form EFFECT
03/30/2026 8:27 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/27/2026 6:40 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/25/2026 3:15 PM
Clearmind Medicine (1892500) Filer
Form POS AM
03/25/2026 3:15 PM
Clearmind Medicine (1892500) Filer
Form POS AM
03/19/2026 3:01 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/17/2026 8:16 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/16/2026 10:12 AM
Clearmind Medicine (1892500) Subject
L.I.A. Pure Capital Ltd (1749628) Filed by
Form SCHEDULE 13G/A
03/16/2026 9:17 AM
Capitalink Ltd. (2036836) Filed by
Clearmind Medicine (1892500) Subject
Form SCHEDULE 13G/A
03/13/2026 6:46 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/12/2026 3:16 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/11/2026 3:01 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/10/2026 8:29 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/09/2026 3:30 PM
Clearmind Medicine (1892500) Subject
Daniel Nissim (2092834) Filed by
Form SCHEDULE 13G/A
03/04/2026 8:01 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/26/2026 11:15 PM
Clearmind Medicine (1892500) Filer
Form EFFECT
02/17/2026 3:44 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/17/2026 3:46 PM
Clearmind Medicine (1892500) Filer
Form F-3
Registration statement for securities of certain foreign private issuers  
02/17/2026 9:48 AM
Clearmind Medicine (1892500) Subject
Iroquois Capital Management, LLC (1481867) Filed by
Form SCHEDULE 13G/A
02/11/2026 3:15 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/09/2026 7:19 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/06/2026 8:53 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/03/2026 7:06 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/01/2026 11:15 PM
Clearmind Medicine (1892500) Filer
Form EFFECT
02/01/2026 11:15 PM
Clearmind Medicine (1892500) Filer
Form EFFECT
02/01/2026 11:15 PM
Clearmind Medicine (1892500) Filer
Form EFFECT
01/27/2026 3:15 PM
Clearmind Medicine (1892500) Filer
Form POS AM
01/27/2026 3:15 PM
Clearmind Medicine (1892500) Filer
Form POS AM
01/27/2026 3:16 PM
Clearmind Medicine (1892500) Filer
Form POS AM
01/14/2026 8:00 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/31/2025 8:13 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/16/2025 7:50 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/12/2025 8:00 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/12/2025 5:35 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/10/2025 3:15 PM
Clearmind Medicine (1892500) Subject
L.I.A. Pure Capital Ltd (1749628) Filed by
Form SCHEDULE 13G/A
12/10/2025 3:15 PM
Capitalink Ltd. (2036836) Filed by
Clearmind Medicine (1892500) Subject
Form SCHEDULE 13G/A
12/10/2025 3:17 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/09/2025 11:15 PM
Clearmind Medicine (1892500) Filer
Form EFFECT
12/05/2025 4:02 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/05/2025 3:52 PM
Clearmind Medicine (1892500) Filer
Form F-1/A
12/05/2025 3:05 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/03/2025 5:04 AM
Clearmind Medicine (1892500) Filer
Form 424B5
12/03/2025 5:06 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/02/2025 7:32 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/01/2025 3:15 PM
Clearmind Medicine (1892500) Subject
L.I.A. Pure Capital Ltd (1749628) Filed by
Form SCHEDULE 13G
12/01/2025 3:15 PM
Capitalink Ltd. (2036836) Filed by
Clearmind Medicine (1892500) Subject
Form SCHEDULE 13G
11/28/2025 3:01 PM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
Rickards Predicts: Trump to buy tiny $2 stock? (Ad)

Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the largest mineral reserve in the country - enough gold for a new Fort Knox, enough copper to rebuild the U.S. electric grid 25 times over. The Trump administration has previously staked positions in MP Materials, Lithium America, Trilogy Metals, and USA Rare Earth - each time shares moved higher. A landmark policy decision expected before November 3 could reprice this stock from $2 to $20 or more within a year.tc pixel

Click here to see why Rickards believes this stock is next
11/28/2025 3:15 PM
Clearmind Medicine (1892500) Subject
Daniel Nissim (2092834) Filed by
Form SCHEDULE 13G
11/26/2025 3:16 PM
Clearmind Medicine (1892500) Filer
Form F-1
Registration statement for securities of certain foreign private issuers  
11/26/2025 7:48 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/26/2025 7:43 AM
Clearmind Medicine (1892500) Filer
Form 424B5
11/20/2025 7:08 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/19/2025 5:05 AM
Clearmind Medicine (1892500) Filer
Form 424B5
11/19/2025 5:09 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/18/2025 5:50 AM
Clearmind Medicine (1892500) Subject
Iroquois Capital Management, LLC (1481867) Filed by
Form SCHEDULE 13G/A
11/17/2025 7:00 AM
Clearmind Medicine (1892500) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)

Clearmind Medicine SEC Filings - Frequently Asked Questions

Clearmind Medicine (CMND) has submitted 216+ filings to the SEC since 2022. You can browse the complete history or filter by form type using the tools above.

Clearmind Medicine's fiscal year ends on October 31. The company typically files its 10-K annual report by the end of December, covering the prior fiscal year's financial results.

The most recent filing was a Form 6-K submitted on September 2, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NASDAQ:CMND are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 9/2/2026. New filings are added as they're published.
From Our Partners